Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 2/20 | 0.62 |
| ▸ | MMP8 | P22894 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313972 | 1.00 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL7855088 | 1.00 | MEN1 (0.68) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL14135235 | 0.86 | MEN1 (0.66) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL7551261 | 0.86 | MEN1 (0.66) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL7551272 | 0.86 | MEN1 (0.66) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL16714831 | 0.84 | MEN1 (0.69) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL28408400 | 0.84 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL12640063 | 0.84 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL12310933 | 0.84 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1MMP9 | |
| SCHEMBL8974575 | 0.84 | MEN1 (0.64) | MEN1KMT2APOLBCTDSP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-8481750-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-12 | — | — | US | disclosed |
| US-7910609-B2 | Inhibitors of integrin alpha2beta1 with modified urea moiety | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-03-22 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7550458-B2 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2008144507-A2 | SPIROOXINDOLE INHIBITORS OF AURORA KINASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-11-27 | — | — | WO | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-19 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | MEN1 4127/4885KMT2A 3209/4885POLB 1702/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | MEN1 4127/4885KMT2A 3209/4885POLB 1702/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | MEN1 1313/4885KMT2A 4426/4885POLB 4192/4885 |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | MEN1 4216/4885KMT2A 2991/4885POLB 2431/4885 |
| US-20120178734-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | ARG1, COL14A1, HPGDS | MEN1 4841/4885KMT2A 2396/4885POLB 4566/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MEN1 3032/4885KMT2A 1449/4885POLB 1939/4885 |
| US-20070088029-A1 | Tricycloundecane compounds useful as modulators of nuclear hormone receptor function | VDR, ESRRB, NR5A1 | MEN1 3781/4885KMT2A 3983/4885POLB 2097/4885 |
| US-20090197861-A1 | INHIBITORS OF INTEGRIN ALPHA2BETA1 WITH MODIFIED UREA MOIETY | ITGA2B, ITGA2, ITGB2 | MEN1 4541/4885KMT2A 3126/4885POLB 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.